Indian Pharmaceutical Market, 2006-2011

Executive Summary

The Indian pharmaceutical market is the 15th largest individual market by sales, but the 4th by volume of product. With domestic drug sales of almost $5 billion, Indian companies have also developed a considerable service industry for the global pharmaceutical market. However the Indian pharmaceutical market looks set for considerable change.
For many years the Indian pharmaceutical market has been seen as a no go area for the R&D based MNCs. The market became dominated by copied generic drugs produced at low-cost by Indian companies. One full year after the introduction of the WTO TRIPS and in the midst of the practical implications of ensuring compliance with product patents, how is the Indian pharmaceutical industry facing up to new regulations to its market?
Indian pharmaceutical companies are able to provide FDA approved facilities for the complete range of services for drug development. R&D services, API sourcing, finished formulation manufacture and clinical trials can all be completed in India, at less cost than in many developed markets. The leading Indian pharmaceutical companies are also beginning to increase market presence and market share in the US and EU markets.

Pivotal period of change…

The Indian pharmaceutical market is entering a pivotal period of change. Although it is unlikely to see significant growth before 2011, visiongain expects extensive company activity as the leading Indian pharmaceutical companies strive towards international competitiveness. Global pharmaceutical companies have already begun to take advantage of the changing regulatory and economic conditions in India. The following five years will see further merger and acquisition activity, including key overseas acquisitions.

The Leading Pharmaceutical Companies Within India

Rank Company

• Ranbaxy Laboratorie
• Cipla
• Dr Reddy’s Laboratories
• Sun Pharmaceuticals
• Nicholas Piramal
• Zydus Cadila
• Biocon
• Glenmark Pharmaceuticals
• Wockhardt Ltd
• Orchid Chemicals

Why you should buy this report

• Significant change is imminent within and from the Indian pharmaceutical market. Global MNCs cannot afford to ignore the cost advantages that the Indian market offers.
• Key companies are examined, recent histories summarised and strategies outlined to provide indications of potential strengths.
• The key IP changes resulting from the acceptance of the WTO TRIPS are outlined.
• This report considers the latest financial and anecdotal information from the Indian pharmaceutical market to enable the most accurate assessment of the medium-term future potential of this $5 billion market.